We are live on ! Find out more
RPTX

Repare Therapeutics

Delisted

RPTX was delisted on the 27th of January, 2026.

71 hedge funds and large institutions have $398M invested in Repare Therapeutics in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 18 increasing their positions, 24 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

62,533% more call options, than puts

Call options by funds: $1.88M | Put options by funds: $3K

0% more funds holding

Funds holding: 7171 (0)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

1.09% less ownership

Funds ownership: 79.36%78.27% (-1.1%)

12% less capital invested

Capital invested by funds: $452M → $398M (-$53.6M)

25% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 24

Holders
71
Holders Change
Holders Change %
0%
% of All Funds
1.22%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
11
Increased
18
Reduced
24
Closed
11
Calls
$1.88M
Puts
$3K
Net Calls
+$1.88M
Net Calls Change
-$598K

RPTX Hedge Fund Activity: Q3 2022 in Review

71 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q3 2022, worth a combined $398M — down 12% from $452M a quarter earlier.

Fund positioning in RPTX was balanced in Q3 2022: 11 funds opened new positions, 11 closed out, 18 added to existing stakes and 24 trimmed.

The largest buyer was CHI Advisors, adding an estimated $5.45M. The largest seller was T. Rowe Price Associates, cutting an estimated $24.7M.

  • 71 institutional investors held Repare Therapeutics (RPTX) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $398M of Repare Therapeutics stock for Q3 2022, down 12% quarter-over-quarter.
  • 11 funds opened new Repare Therapeutics positions in Q3 2022 and 11 closed out, a net change of 0 holders.
  • The largest Repare Therapeutics buyer in Q3 2022 was CHI Advisors, an estimated $5.45M added.
  • The largest Repare Therapeutics seller in Q3 2022 was T. Rowe Price Associates, an estimated $24.7M sold.

Based on aggregated 13F filings for Q3 2022.